Shares of HCP, Inc. (NYSE:HCP) have earned a consensus rating of “Buy” from the sixteen brokerages that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $31.22.
HCP has been the subject of a number of analyst reports. Raymond James initiated coverage on shares of Adverum Biotechnologies in a research report on Thursday, June 13th. They issued a “market perform” rating for the company. TheStreet upgraded shares of Rent-A-Center from a “c” rating to a “b-” rating in a research report on Tuesday, May 7th. Morgan Stanley set a $111.00 price objective on shares of Procter & Gamble and gave the company a “buy” rating in a research report on Thursday, March 28th. Finally, KeyCorp downgraded shares of GTT Communications from an “overweight” rating to a “sector weight” rating in a research report on Monday, July 1st.
Shares of NYSE HCP traded down $0.90 during midday trading on Friday, reaching $31.74. The company’s stock had a trading volume of 1,859,787 shares, compared to its average volume of 2,588,113. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 0.90. HCP has a fifty-two week low of $24.47 and a fifty-two week high of $33.58. The stock’s 50 day moving average price is $32.21. The firm has a market cap of $15.17 billion, a P/E ratio of 17.44, a P/E/G ratio of 7.09 and a beta of 0.31.
In other HCP news, Director Christine Garvey sold 3,405 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $29.80, for a total transaction of $101,469.00. Following the completion of the transaction, the director now directly owns 5,348 shares in the company, valued at $159,370.40. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.13% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Comerica Securities Inc. acquired a new stake in HCP in the fourth quarter valued at $345,000. Raymond James Financial Services Advisors Inc. grew its holdings in HCP by 13.0% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 39,004 shares of the real estate investment trust’s stock valued at $1,089,000 after purchasing an additional 4,492 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of HCP by 32.9% during the fourth quarter. Bessemer Group Inc. now owns 1,332 shares of the real estate investment trust’s stock valued at $37,000 after acquiring an additional 330 shares during the last quarter. United Services Automobile Association boosted its stake in shares of HCP by 30.7% during the fourth quarter. United Services Automobile Association now owns 192,035 shares of the real estate investment trust’s stock valued at $5,364,000 after acquiring an additional 45,064 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of HCP by 11.8% during the fourth quarter. Geode Capital Management LLC now owns 7,752,843 shares of the real estate investment trust’s stock valued at $216,236,000 after acquiring an additional 821,285 shares during the last quarter. Institutional investors and hedge funds own 95.50% of the company’s stock.
HCP Company Profile
HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.
Featured Article: Options Trading
Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.